Powered by: Motilal Oswal
2025-03-01 03:54:39 pm | Source: PR Agency
Strand Life Sciences Launches Portal to Help Doctors with Rare Disease Diagnosis; Offers Discounted Testing for Low-Income Patients
Strand Life Sciences Launches Portal to Help Doctors with Rare Disease Diagnosis; Offers Discounted Testing for Low-Income Patients

On the occasion of Rare Disease Day, Strand Life Sciences, a Reliance Industries subsidiary and leading genomics company, today launched the StrandOmics Portal to improve diagnosis of rare diseases.

This new online portal gives clinicians quick and easy access to information on genetic variants, giving them a comprehensive view for each case. This means faster and more accurate diagnosis for patients.

In addition to the portal, Strand Life Sciences will offer rare disease genetic testing at a reduced cost for patients from economically disadvantaged backgrounds, making these crucial tests more accessible.

The StrandOmics Portal helps doctors by:

* Providing clear and quick genetic insights for better diagnosis

* Allowing doctors to independently review a broader set of genetic variants

* Improving prenatal diagnosis through better collaboration between specialists

Dr. Ramesh Hariharan, CEO & Co-Founder of Strand Life Sciences, said, “We are dedicated to improving genetic diagnostics and making it available to everyone. We will continue to innovate and invest in tools like the StrandOmics Portal to empower doctors in their fight against rare diseases.”

 

Above views are of the author and not of the website kindly read disclaimer

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here